Lotus Eye Hospital and Institute Limited (LOTUSEYE) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.6B
Fair value as of: Aug 13, 2026
From 12 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹80.97 to ₹81.06 (+0.1%) since Aug 8, 2026. Share price −5.1% over the past month.
Below-average quality, and screening another 30% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹101.08). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹39.62 – ₹141.38 · fair‑value band ₹61.03 – ₹101.08 · the ₹115.83 price screens above the ₹81.06 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Lotus Eye Hospital and Institute Limited (LOTUSEYE) currently trades at ₹115.83, while our model-based Fair Value estimate is ₹81.06, implying the stock looks roughly 30.0% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Lotus Eye Hospital and Institute Limited generated revenue of ₹537M at a net margin of 0.2%. Revenue grew 18.2% year over year. It earns a return on equity of 0.1%. Net debt stands at ₹120M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹61.03 (bear case) to ₹101.08 (bull case); at ₹115.83, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 64% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -30%, LOTUSEYE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Asset-Based (₹1,847) versus Dividend Discount (₹7.63). Highest evidence: Residual Income (76).
Notify me when LOTUSEYE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India.
Full company description
Lotus Eye Hospital and Institute Limited, a specialty eye care hospital, provides eye care and related services in India. The company offers ReLEx SMILE, a refractive lenticule extraction small incision lenticule extraction; touch free laser; lasik eye surgery; Epi-LASIK, an epithelial laser in situ keratomileusis; Intralase, a blade-free technique to create the corneal flap; Zyoptix Supracor laser technology; robotic femto laser cataract surgery; phacoemulsification; paediatric eye care and squint surgery; and micro incision cataract surgery treatments. It provides treatment services for various eye problems, such as refractive, cataract, glaucoma, retinal disease/diabetic eye care, neuro ophthalmology, binocular vision, and cornea infections, as well as various eye related courses. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was founded in 1989 and is based in Coimbatore, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lotus Eye Hospital and Institute Limited reported revenue of ₹537M in FY2026 versus ₹389M in FY2022, a compound +8.4%/yr. Reported net income was ₹804K in FY2026, compounding −59.5%/yr from FY2022.
LOTUSEYE screens 30% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare Lotus Eye Hospital and Institute Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lotus Eye Hospital and Institute Limited (LOTUSEYE) overvalued or undervalued?
What is the fair value of LOTUSEYE?
What is the quality score of LOTUSEYE?
What is the revenue of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
What is the net profit margin of LOTUSEYE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lotus Eye Hospital and Institute Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.